Interventional Glaucoma

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

Steel and the Glaucoma Research Foundation have a relationship spanning over a decade.

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Can AI compete with the well-oiled machine of the contemporary clinic?

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

The law will work to remove outdated restrictions on medications and allow some in-office procedures and will take effect in August.

Jim Mazzo is among the presenters who will highlight the need to break silos and accelerate eye health solutions at the Collaborative Community on Ophthalmic Innovation (CCOI) meeting at Stanford University on July 23, 2025.

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

All 696 patients in the trial have completed their treatment and follow-up visits.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

The framework covers ocular hypertension to severe progression

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.